<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000600472">
  <TermName>Angiocept</TermName>
  <TermPronunciation>(AN-jee-oh-sept)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance being studied in the treatment of cancer. Angiocept may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor and a type of antiangiogenesis agent. Also called CT-322 and VEGFR-2 inhibitor CT-322.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000720635" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Angiocept&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000720634" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Angiocept&quot;" language="es" id="_4"/>
  <SpanishTermName>Angiocept</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento del cáncer. Angiocept quizás impida la formación de vasos sanguíneos nuevos que los tumores necesitan para crecer y es posible que destruya células cancerosas. Es un tipo de antiangiogénico y de inhibidor del receptor del factor de crecimiento endotelial vascular-2 (VEGFR-2). También se llama CT-322 e inhibidor del VEGFR-2 CT-322.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2008-07-14</DateFirstPublished>
  <DateLastModified>2009-04-21</DateLastModified>
</GlossaryTerm>
